ONESOURCE SPECIALTY
GenericsONESOURCE SPECIALTY is a generic drug manufacturer focused on Infectious Disease, Immunology, Gastroenterology.
ONESOURCE SPECIALTY's Key Drugs
ONESOURCE SPECIALTY's core commercial portfolio centers on MIDOZALAM HYDROCHLORIDE, spanning Infectious Disease and Immunology — its most strategically important drugs approved in the last 15 years.
ONESOURCE SPECIALTY's Recent FDA Approvals
New NDA/BLA approvals for ONESOURCE SPECIALTY over the last two years — novel drugs only, excluding generics and label supplements.
ONESOURCE SPECIALTY's Therapeutic Areas
ONESOURCE SPECIALTY's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Immunology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ONESOURCE SPECIALTY's Top Competitors
ONESOURCE SPECIALTY's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ONESOURCE SPECIALTY Pipeline Snapshot
Active clinical trials for ONESOURCE SPECIALTY across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • MIDOZALAM HYDROCHLORIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1986-12-30
- Latest
- 2026-04-15
- Applications
- 46